enalkiren has been researched along with Heart Failure in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boger, RS; Granneman, GR; Gupta, SK; Packer, M | 1 |
| Foote, EF; Halstenson, CE | 1 |
| Kukin, ML; Medina, N; Neuberg, GW; Packer, M; Penn, J; Yushak, M | 1 |
1 review(s) available for enalkiren and Heart Failure
| Article | Year |
|---|---|
New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Dipeptides; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Renin; Tetrazoles | 1993 |
2 trial(s) available for enalkiren and Heart Failure
| Article | Year |
|---|---|
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Animals; Dipeptides; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Rabbits; Renin | 1993 |
Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Renin; Renin-Angiotensin System | 1991 |